Holostem’s pipeline includes Advanced Therapy Medicinal Products at different stage of development.
| Product | Indication | Preclinical | Phase I/II |
Phase III |
Regulatory Approval | ||
| Ex vivo reconstructed autologous human corneal epithelium containing stem cells | Limbal stem cell deficiency | Full Approval | |||||
| Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector | Junctional Epidermolysis Bullosa | ||||||
| Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7-encoding retroviral vector | Dystrophic Epidermolysis Bullosa | ||||||
| Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector | Junctional Epidermolysis Bullosa | ||||||
Our research activity is aimed to develop new protocols for cell and gene therapy based on different types of epithelial stem cells.
